Brand amplification UK Register to read

Brand analysis: UK pharmacy obesity treatments, June 2026

One brand is named on more than two thirds of UK community pharmacies stocking obesity treatments. Generic orlistat carries the second tier, ahead of two GLP-1 injectables sharing third place.

By Rare.Monitor analyst team Published 11 June 2026

June 2026 / Weight mgmt / UK

Obesity Pharmaceuticals Pharmacy Weight Management

Top 3 brands by community-pharmacy mention rate

01Alli68.8%
02Orlistat (generic) Register to see
03Wegovy Register to see

Source: Rare.Monitor, June 2026. 2,518 UK GPHC-registered community pharmacies audited.

RARE

OTC, prescription oral and prescription injectable obesity brands across UK GPHC-registered community pharmacies.

Brands tracked in this analysis

Adipex
Alevere
Alli
Dimagra
Liraglutide
Lomaira
Mounjaro
Mysimba
Orlistat
Ozempic
Saxenda
Semaglutide
Tenuate
Tepanil
Wegovy

Registered access

See the full ranking

Free. Takes 30 seconds. · Rare.Monitor tracks over 230,000 UK health, wellness and beauty places · MRS · ABPI · BHBIA member

More on this analysis

Which obesity brand is named most often by UK community pharmacies in 2026?

GlaxoSmithKline's Alli leads UK community-pharmacy obesity brand mentions at 68.8%, based on Rare.Monitor's June 2026 audit of 2,518 GPHC-registered community pharmacies active in obesity treatments.

How does Mounjaro compare to Wegovy in UK community pharmacies?

Across 2,518 UK GPHC-registered community pharmacies audited in June 2026, Novo Nordisk's Wegovy and Eli Lilly's Mounjaro are effectively tied at 24.3% and 24.1% mention rate respectively (Rare.Monitor).

What is the difference between Alli and generic orlistat in UK community-pharmacy listings?

Alli is GlaxoSmithKline's over-the-counter orlistat 60mg brand. The generic Orlistat row in the Rare.Monitor analysis primarily reflects the prescription-only orlistat 120mg formulation dispensed by multiple generic manufacturers. The two share the same active molecule at different doses and dispensing tiers, so the rows are not competing products from different manufacturers.

Why does Ozempic appear on UK community-pharmacy obesity listings?

Ozempic is licensed in the UK for Type 2 diabetes. It appears at a 1.8% mention rate across the 2,518 UK GPHC-registered community pharmacies audited in June 2026 (Rare.Monitor). The data measures the presence of a brand name on a pharmacy listing; it does not record the indication for which Ozempic is dispensed at each location.

Which manufacturer has the broadest obesity brand footprint in UK community pharmacies?

Novo Nordisk has the widest brand footprint in the June 2026 Rare.Monitor audit of UK community pharmacies, with five obesity-licensed or obesity-adjacent products tracked (Wegovy, Semaglutide, Ozempic, Saxenda, Liraglutide). On single-brand mention rate, GlaxoSmithKline's Alli leads at 68.8%, ahead of generic orlistat at 44.4% and the GLP-1 injectables Wegovy (24.3%) and Mounjaro (24.1%).

How many UK community pharmacies were audited for the June 2026 obesity brand analysis?

Rare.Monitor audited 2,518 UK GPHC-registered community pharmacies active in obesity treatments in June 2026. Mention rates are calculated against this audited cohort.

Brand analysis: UK pharmacy obesity treatments, June 2026

See the full ranking

Obesity in England, where the burden falls

Pioneering the healthcare industry: What new drugs are coming to the market?

Self pay: A new opportunity for weight loss

More on this analysis

See what Rare.Monitor would do for your numbers.